In the meantime, the GLP-1 discontinuation wave from Semaglutide and Tirzepatide alone is already creating significant downstream demand, for metabolic support products, muscle preservation, and micronutrient replenishment
Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, et al
The interplay between adipokines and body composition in obesity and metabolic diseases
Fascinatingly, the Survodutide studies that I mentioned previously, they measured the number of patients in the placebo group that ultimately were taking another GLP-1 on their own accord and that actually led, that was 20% of that placebo group by the end of the trial actually were taking a GLP-1